Mohammed Ali, Z.; Meertens, M.; Fernández, B.; Fontova, P.; Vidal-Alabró, A.; Rigo-Bonnin, R.; Melilli, E.; Cruzado, J.M.; Grinyó, J.M.; Colom, H.;
et al. CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach. Pharmaceutics 2023, 15, 2699.
https://doi.org/10.3390/pharmaceutics15122699
AMA Style
Mohammed Ali Z, Meertens M, Fernández B, Fontova P, Vidal-Alabró A, Rigo-Bonnin R, Melilli E, Cruzado JM, Grinyó JM, Colom H,
et al. CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach. Pharmaceutics. 2023; 15(12):2699.
https://doi.org/10.3390/pharmaceutics15122699
Chicago/Turabian Style
Mohammed Ali, Zeyar, Marinda Meertens, Beatriz Fernández, Pere Fontova, Anna Vidal-Alabró, Raul Rigo-Bonnin, Edoardo Melilli, Josep M. Cruzado, Josep M. Grinyó, Helena Colom,
and et al. 2023. "CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach" Pharmaceutics 15, no. 12: 2699.
https://doi.org/10.3390/pharmaceutics15122699
APA Style
Mohammed Ali, Z., Meertens, M., Fernández, B., Fontova, P., Vidal-Alabró, A., Rigo-Bonnin, R., Melilli, E., Cruzado, J. M., Grinyó, J. M., Colom, H., & Lloberas, N.
(2023). CYP3A5*3 and CYP3A4*22 Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach. Pharmaceutics, 15(12), 2699.
https://doi.org/10.3390/pharmaceutics15122699
